Literature DB >> 19482780

Critical review: is watchful waiting a viable management option for older men with prostate cancer?

Donald E Bailey1, Meredith Wallace.   

Abstract

Prostate cancer is the most commonly diagnosed cancer and the second-leading cause of death from cancer in U.S. men. For older men with early-stage prostate cancer, watchful waiting (also referred to as surveillance, expectant management, deferred/delayed therapy, or active monitoring) is a reasonable approach to aggressive therapy. The purpose of this article is to critically review published studies on the watchful waiting management option for prostate cancer within the past 5 years. The review of documented reports on watchful waiting reveals that there are both negative and positive indications toward watchful waiting. Further research is needed to change the perception of watchful waiting as a "do nothing" approach to the management of prostate cancer or a "death sentence" and to develop interventions that assist men to manage the uncertainty associated with living with prostate cancer to improve health and advance quality of life.

Entities:  

Mesh:

Year:  2007        PMID: 19482780     DOI: 10.1177/1557988306294161

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  3 in total

1.  Measuring illness uncertainty in men undergoing active surveillance for prostate cancer.

Authors:  Donald E Bailey; Meredith Wallace; David M Latini; Josephine Hegarty; Peter R Carroll; Eric A Klein; Peter C Albertsen
Journal:  Appl Nurs Res       Date:  2009-09-18       Impact factor: 2.257

2.  Patient perspective on watchful waiting/active surveillance for localized prostate cancer.

Authors:  Jinping Xu; Anne Victoria Neale; Rhonda K Dailey; Susan Eggly; Kendra L Schwartz
Journal:  J Am Board Fam Med       Date:  2012 Nov-Dec       Impact factor: 2.657

3.  Expression and significance of PTEN and Claudin-3 in prostate cancer.

Authors:  Xinglong Ye; Lijing Zhao; Jing Kang
Journal:  Oncol Lett       Date:  2019-04-03       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.